Replication-competent retroviruses in gene-modified T cells used in clinical trials: Is it time to revise the testing requirements?

Adham S. Bear, Richard A. Morgan, Kenneth Cornetta, Carl H. June, Gwendolyn Binder-Scholl, Mark E. Dudley, Steven A. Feldman, Steven A. Rosenberg, Sheila A. Shurtleff, Cliona M. Rooney, Helen E. Heslop, Gianpietro Dotti

Research output: Contribution to journalComment/debate

36 Scopus citations
Original languageEnglish (US)
Pages (from-to)246-249
Number of pages4
JournalMolecular Therapy
Volume20
Issue number2
DOIs
StatePublished - Feb 2012

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Bear, A. S., Morgan, R. A., Cornetta, K., June, C. H., Binder-Scholl, G., Dudley, M. E., Feldman, S. A., Rosenberg, S. A., Shurtleff, S. A., Rooney, C. M., Heslop, H. E., & Dotti, G. (2012). Replication-competent retroviruses in gene-modified T cells used in clinical trials: Is it time to revise the testing requirements? Molecular Therapy, 20(2), 246-249. https://doi.org/10.1038/mt.2011.288